Table A23:
Results of Change in HAM-D17 Depression Scores With Less Than 8-Week Follow-Up
| Author, Year | N PGx/TAU | Mean at Follow-up (SD) | % Decrease from Baseline to Follow-Up | P Valuea | ||
|---|---|---|---|---|---|---|
| PGx | TAU | PGx | TAU | |||
| Genesight | ||||||
| Winner et al, 201365 | 6 wk: 25/24 4 wk: 25/24 |
NR NR |
NR NR |
35.4 28.3 |
18.5 19.8 |
.04 .27 |
| Hall-Flavin et al, 201355 | 4 wk: 72/93 2 wk: 72/93 |
NE NE |
NE NE |
NR NR |
NR NR |
.0002 NS |
| Hall-Flavin et al, 201256 | 4 wk: 22/22 2 wk: 22/22 |
NE NE |
NE NE |
NR NR |
NR NR |
NS NS |
| Neuropharmagen | ||||||
| Perez et al, 201762 | 6 wk: 146/146 | NE | NE | NR | NR | .036 |
| Other | ||||||
| Shan et al, 201963 | 4 wk: 31/40b 2 wk: 31/40b |
10.68 (4.17) 12.77 (4.67) |
11.03 (4.83) 13.33 (4.27) |
48.50 38.66 |
46.87 35.78 |
MD: 0.901 MD: 0.696 |
| Genecept | ||||||
| Perlis et al, 202061 | 6 wk: 146/150 4 wk: 146/150 2 wk: 146/150 |
13.93 (7.04) 15.43 (6.67) 17.39 (5.95) |
14.02 (7.17) 15.66 (6.42) 17.77 (5.77) |
38.05c 31.74c 22.76c |
35.34c 28.50c 19.60c |
.444c .306c .246c |
Abbreviations: MD, mean difference; NE, not estimated; NR, not reported; NS, not significant; PGx, pharmacogenomic-guided treatment selection; SD, standard deviation; TAU, treatment as usual.
a
P values reflect differences in percent decrease from baseline to follow-up unless otherwise noted.
b
Based on full analysis set (intention-to-treat analysis).
c
Values for mixed effects models with repeated measures.